User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

461

Interactions with Platform & by Email *

INTERACTIONS

92

Unique # Participated *

PARTICIPANTS

18

Responses Validated *

VALIDATIONS

7

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Biosimulation: Massively Benefiting Drug R&D.....II-1
Current and Future Analysis.....II-1
Application and End-user Areas.....II-1
1$100
   Table 1: Global Biosimulation Market by Application (2014): Percentage Share of Revenue in Drug Development, Drug Discovery, and Others (includes corresponding Graph/Chart).....II-2

Table 2: Global Biosimulation Market by End-user Sector (2014): Percentage Share of Revenue for Academic Research Institutes, Biotechnology/Drug Companies, Contract Research Organizations (CROs), Regulatory Organizations, and Others (includes corresponding Graph/Chart).....II-2
1$350
   Biosimulation Offers Paradigm Shift in Drug Development.....II-3
Key Market Drivers in a Nutshell.....II-3
Market Restraints.....II-3
1$100
   Competition.....II-41$100
   Increasing Healthcare Expenditure Drives the Need for Drug Discovery and
  Development.....II-5
1$100
   Table 3: Per Capita Healthcare Expenditure in US$ by Select Country (includes corresponding Graph/Chart).....II-61$350
   Table 4: Healthcare Expenditure as % of GDP by Select Country (includes corresponding Graph/Chart).....II-71$350
   Increasing Incidence and Prevalence of CDDs: A Major Growth Driver.....II-8
Table 5: Worldwide Incidence of Cancer in Million: 2012, 2020 & 2030 (includes corresponding Graph/Chart).....II-8
1$350
   Table 6: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart).....II-9
Aging Global Population Drives Advanced Drug R&D.....II-9
1$350
   Table 7: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart).....II-101$350
   Table 8: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart).....II-11
High Costs Associated with Traditional Drug Discovery.....II-11
1$350
   Table 9: Escalating Costs of New Drug Development Over the Decades (includes corresponding Graph/Chart).....II-121$350
   Table 10: US R&D Productivity Trends in Pharma Industry (2006- 2013) (includes corresponding Graph/Chart).....II-13
High Failure Rate of Late-Stage Drug Trials.....II-13
1$350
   List of Recent Late-stage Drug Failures (2014).....II-14
China and India: Hot Spots for R&D Investment.....II-14
1$100
   Table 11: Percentage Breakup of Global R&D Spending by Region (2012) (includes corresponding Graph/Chart).....II-15
Biosimulation Overcomes Challenges in Pediatric Drug Development.....II-15
1$350
   Simulation Tools Take the Pressure off Mounting Life Science R&D Budgets.....II-16
Table 12: Global Life Science R&D Expenditure (2011-2014): Total R&D Spending in US$ Billion (includes corresponding Graph/Chart).....II-16
Biosimulation Gets Neurodegenerative Disease Out of the Cul-de-sac.....II-16
1$350
   Marking New Avenues in Diabetes Research.....II-17
Biosimulation Moving From Discovery Aid to Clinical Tool.....II-17
1$100
   Lung Biosimulation: Game Changer for OIP Development.....II-18
Biosimulation for Drug Repositioning.....II-18
1$100
   Grid-based Docking Aids Biosimulation.....II-19
Need for Better Models: A Major Factor Driving Innovation in the Market.....II-19
2$200
   Biosimulation - A Brief Introduction.....II-21
Drug Discovery and Development.....II-21
1$100
   Stages in Drug Development Process.....II-22
Target identification.....II-22
Target Validation.....II-22
1$100
   Lead Identification.....II-23
Lead Optimization.....II-23
Pre-Clinical Testing.....II-23
1$100
   Clinical Trials.....II-24
Drug Discovery Technologies.....II-24
1$100
   Human Physiology.....II-25
Mathematical Models and Biosimulation Technique.....II-25
1$100
   Bottom-up Modeling.....II-26
Top-Down Modeling.....II-26
1$100
   Certara Launches Simcyp In Vitro Analysis Toolkit Version 1.0.....II-27
Optimata Granted US Patent for Biosimulation Technology.....II-27
Cognigen Releases Version 1.3 of KIWI™.....II-27
Simulations Plus Releases Version 9.0 of GastroPlus™.....II-27
Certara Launches Version 2.0 of Cardiac Safety Simulator.....II-27
Certara Releases Version 14 of Simcyp™ Simulator.....II-27
Certara Receives FDA Grant for MechDermA.....II-27
1$100
   Physiomics Launches EasyAP™.....II-28
Rhenovia Pharma Develops Simulator for Epilepsy Mechanisms.....II-28
Insilico Biotechnology Launches Simulation Platform for Virtual Organs.....II-28
1$100
   Certara Merges Its Pharsight Consulting with Quantitative Solutions.....II-29
Optivia Biotechnology and Rhenovia Pharma Sign Partnership Agreement.....II-29
Physiomics Signs Contract with Merck Serono.....II-29
PMDA Equips Pharmacometrics Team with Certara’s Biosimulation Solutions.....II-29
CQDM and Alsace-Biovalley Collaborate on Biosimulation Platform.....II-29
Dassault Systèmes Acquires Accelrys.....II-29
1$100
   Rhenovia Pharma Secures Series B Funding.....II-30
Pharmacelsus and Insilico Biotechnology Collaborate for Preclinical Drug
  Analysis.....II-30
Arsenal Capital Partners Acquires Certara.....II-30
Entelos Enters Into Licensing Agreement with USFDA.....II-30
1$100
   Advanced Chemistry Development, Inc. (Canada).....II-31
Biovia (Formerly Accelrys) (US).....II-31
Certara L.P. (US).....II-31
1$100
   Chemical Computing Group (Canada).....II-32
Entelos, Inc. (US).....II-32
1$100
   In Silico Biosciences, Inc. (US).....II-33
InhibOx (UK).....II-33
Insilico Biotechnology AG (Germany).....II-33
LeadInvent Technologies (India).....II-33
1$100
   Leadscope, Inc. (US).....II-34
Nimbus Therapeutics (US).....II-34
OpenEye Scientific Software Inc. (US).....II-34
Physiomics Plc. (UK).....II-34
1$100
   Rhenovia Pharma SAS (France).....II-35
Schrodinger, LLC (US).....II-35
Simulations Plus, Inc.(US).....II-35
2$200
   Table 13: World Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....II-371$350
   Table 14: World 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart).....II-381$350
   A. Market Analysis.....III-1
Biosimulation to Abate Life Sciences R&D Spending.....III-1
Table 15: The US Life Science Industry Annual R&D Expenditure: 2011-2014 (includes corresponding Graph/Chart).....III-1
1$200
   Ageing Population – Booster for Effective Drug Development.....III-2
Table 16: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-2
1$200
   Rise in Chronic Disorders Drive Market Growth.....III-3
Table 17: US Diabetics Population (2010-2017): Percentage Population with Diagnosed and Undiagnosed Diabetes (includes corresponding Graph/Chart).....III-3
1$200
   Table 18: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Age Groups (includes corresponding Graph/Chart).....III-4

Table 19: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Ethnic Group (includes corresponding Graph/Chart).....III-4
1$200
   Table 20: New Cancer Cases in the US by Gender and Affected Site: 2014E (includes corresponding Graph/Chart).....III-51$200
   Product Launches.....III-61$75
   Strategic Corporate Developments.....III-7
Key Players.....III-7
4$300
   B. Market Analytics.....III-11
Table 21: The US Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-11
1$200
   A. Market Analysis.....III-12
Increasing Incidence of Cancer: A Major Growth Driver.....III-12
Table 22: New Cancer Cases in Canada by Gender and Affected Site: 2014E (includes corresponding Graph/Chart).....III-12
1$200
   Strategic Corporate Development.....III-13
Key Players.....III-13
1$75
   B. Market Analytics.....III-14
Table 23: Canadian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-14
1$200
   A. Market Analysis.....III-15
Graying Population Spurs Demand for Advanced Drug Development.....III-15
Table 24: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart).....III-15
Strategic Corporate Development.....III-15
1$200
   B. Market Analytics.....III-16
Table 25: Japanese Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-16
1$200
   A. Market Analysis.....III-17
Regulatory Authorities Stress on Paradigm Shift in Drug Development.....III-17
Ageing Population Boosts Demand.....III-17
1$75
   Table 26: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart).....III-181$200
   B. Market Analytics.....III-19
Table 27: European Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-19
1$200
   Table 28: European 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart).....III-201$200
   A. Market Analysis.....III-21
Strategic Corporate Developments.....III-21
Rhenovia Pharma SAS – A Key Player.....III-21
1$75
   B. Market Analytics.....III-22
Table 29: French Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-22
1$200
   A. Market Analysis.....III-23
Product Launch.....III-23
Strategic Corporate Development.....III-23
Insilico Biotechnology AG – A Key Player.....III-23
1$75
   B. Market Analytics.....III-24
Table 30: German Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-24
1$200
   Market Analysis.....III-25
Table 31: Italian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-25
1$200
   A. Market Analysis.....III-26
Product Launch.....III-26
Strategic Corporate Development.....III-26
Key Players.....III-26
1$75
   B. Market Analytics.....III-27
Table 32: The UK Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-27
1$200
   Market Analysis.....III-28
Table 33: Spanish Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-28
1$200
   Market Analysis.....III-29
Table 34: Russian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-29
1$200
   Market Analysis.....III-30
Table 35: Rest of European Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-30
1$200
   A. Market Analysis.....III-31
Growing Population and Aging Demographic Drive Demand for Advanced Drug
  Development.....III-31
Table 36: Population Statistics in Asia (Including Japan) & Percentage of Population Aged Above 65 Years (includes corresponding Graph/Chart).....III-31
1$200
   Leadinvent Technologies (India) – A Key Player.....III-32
B. Market Analytics.....III-32
Table 37: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-32
1$200
   Market Analysis.....III-33
Table 38: Latin American Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-33
1$200
   A. Market Analysis.....III-34
Product Launch.....III-34
B. Market Analytics.....III-34
Table 39: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-34
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com